West Pharmaceutical Services said consolidated net sales for the quarter ended March 31, 2024 decreased $21.2 million, or 3.0%, from the prior-year period. This included a favorable foreign currency translation impact of $3.4 million.

10-QQuarterly reportFiled Apr 25, 2024Period of report Mar 31, 2024Summary published (UTC) Oct 24, 2026

Key points

AI summary

West Pharmaceutical Services said consolidated net sales for the quarter ended March 31, 2024 decreased $21.2 million, or 3.0%, from the prior-year period. This included a favorable foreign currency translation impact of $3.4 million.
The company said Proprietary Products net sales fell $23.6 million, or 4.0%. Excluding foreign currency translation effects and the removal of sales from a plant disposed of in 2023, it cited lower sales of FluroTec® products, Westar® components and standard components as the main factors. It said increased sales of NovaPure® products, among others, and higher sales prices partly offset these declines.
The company said consolidated gross profit decreased $41.1 million, or 15.1%, from the prior-year period, and consolidated gross profit margin fell 4.8 margin points. It cited lower sales volume and an unfavorable product mix as reasons for the lower Proprietary Products gross profit margin.
West Pharmaceutical Services said it repurchased 729,679 shares of its common stock for $267.0 million, at an average price of $365.87 per share, during Q1 2024. Net cash used in financing activities rose $200.0 million, and the company attributed the increase mainly to higher share repurchases.

Key figures

Quarter ended March 31, 2024

Revenue: $695M
Operating income: $123M
Net income: $115M
EPS: $1.55
Gross profit: $230M
Operating cash flow: $118M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Consolidated Net Sales Down 3.0%

West Pharmaceutical Services said consolidated net sales for the quarter ended March 31, 2024 decreased $21.2 million, or 3.0%, from the prior-year period. This included a favorable foreign currency translation impact of $3.4 million.

Source · Based on the MD&A text of the filing

Proprietary Products Sales Down 4.0%

The company said Proprietary Products net sales fell $23.6 million, or 4.0%. Excluding foreign currency translation effects and the removal of sales from a plant disposed of in 2023, it cited lower sales of FluroTec® products, Westar® components and standard components as the main factors. It said increased sales of NovaPure® products, among others, and higher sales prices partly offset these declines.

Source · Based on the MD&A text of the filing

Consolidated Gross Profit Down 15.1%

The company said consolidated gross profit decreased $41.1 million, or 15.1%, from the prior-year period, and consolidated gross profit margin fell 4.8 margin points. It cited lower sales volume and an unfavorable product mix as reasons for the lower Proprietary Products gross profit margin.

Source · Based on the MD&A text of the filing

Share Buybacks Lift Cash Used in Financing

West Pharmaceutical Services said it repurchased 729,679 shares of its common stock for $267.0 million, at an average price of $365.87 per share, during Q1 2024. Net cash used in financing activities rose $200.0 million, and the company attributed the increase mainly to higher share repurchases.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.